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Michael McDevitt,1,2 Mark Levis1Acute myelogenous leukemia (AML) patients with FLT3/ITDmutations have an inferior survival compared to
AML patients with wild-type (WT) FLT3, primarily because of an increased relapse rate. Allogeneic transplan-
tation represents a postremission therapy that is effective at reducing the risk of relapse for many cases of
poor-risk AML.Whether or not allogeneic transplantation in first complete remission (CR) can improve out-
comes for patients with FLT3/ITD AML remains controversial. Our institution has adopted a policy of pur-
suing allogeneic transplantation, including the use of alternate donors, for FLT3/ITD AML patients in
remission. As part of an instituional review board–approved study, we performed a review of the clinical
data from November 1, 2004, to October 31, 2008, on all adult patients under the age of 60 presenting
in consecutive fashion to the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins with newly
diagnosed non-M3 AML. We followed their outcomes through August 1, 2010. During the study period,
133 previously untreated AML patients between the ages of 20 and 59 were diagnosed and received induc-
tion and consolidation therapy at our institution. Of these 133 patients, 31 (23%) harbored an FLT3/ITD mu-
tation at diagnosis. The median overall survival (OS) from the time of diagnosis for the FLT3/ITD AML
patients was compared to the OS of the entire cohort and found to be comparable (19.3 months versus
15.5 months, P5.56). Historically, OS for FLT3/ITDAML patients is significantly worse than for AML patients
lacking this mutation. However, the OS for the 31 FLT3/ITD patients reported here was comparable to the
102 patients withWT FLT3 over the same 4-year time period. One difference that might have contributed to
the surprising outcomes for the FLT3/ITD group is our aggressive pursuit of allogeneic bone marrow trans-
plant (BMT) in CR1 within this group (60% of FLT3/ITD versus 17% withWT). Our single-institution study of
consecutively treated AML patients supports the hypothesis that allogeneic transplant in early CR1 improves
the long-term outcomes for FLT3/ITD AML.
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initial induction therapy (CR1) now approaches 80%
[1]. However, many of these patients will eventually re-
lapse and die from their AML.
Attention has recently focused on determining the
post remission therapiesmost likely to decrease rates of
relapse. Following successful allogeneic hematopoietic
stem cell transplantation (HSCT) [1], the relapse rate
is significantly reduced. However, the use of HSCT
is limited by treatment-related morbidity and mortal-
ity. Continuing studies ofHSCT are required to deter-
mine which patients will most benefit from this therapy
with its associated morbidity and mortality.
The choice of HSCT as post-remission therapy is
guided by prognostic indicators [2]. Cytogenetic risk
has been widely used to explore the efficacy of
HSCT for patients with AML in CR1. In adults with
AML, the karyotype at the time of diagnosis is the
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patients with unfavorable-risk cytogenetics, the bene-
ficial effect of allogeneic HSCT has been demon-
strated in a large meta-analysis [4]. However, up to
50% of patients do not have clonal chromosomal aber-
rations [5] usable for this prognostication. Therefore,
there is a need to determine other prognostic markers
beyond conventional cytogenetics. FLT3/ITD is such
a prognostic marker.
In 1996, it was reported that internal tandem dupli-
cation (ITD) of base pairs of the FMS-Like-Tyrosine
kinase-3 (FLT3) could result in the constitutive activa-
tion of the gene in AML patients [6]. These mutations
in FLT3 are found in about 30% of cases of AML and
confer an increased relapse rate and reduced overall
survival (OS) [7-10].
To further investigate whether this prognostic
marker could be used to guide the decision to move to-
ward earlierHSCT,our institutionhas adopted a policy
of pursuing allogeneicHSCT for FLT3/ITDAMLpa-
tients inCR1.Here, wepresent the data from31FLT3/
ITDpatients age 18 to 59.9 years, and compare the out-
comes for patients receiving allogeneic HSCT in CR1
with that for patientswho received chemotherapy alone.MATERIALS AND METHODS
Data Sources
We reviewed the clinical databases at the Sidney
Kimmel Comprehensive Cancer Center (SKCCC) at
Johns Hopkins Hospital in Baltimore. Our observa-
tional study was carried out with a waiver of informed
consent, in accordancewith theDeclaration ofHelsinki,
and in compliancewith theHealth InsurancePortability
Accountability Act regulations as determined by the In-
stitutionalReviewBoardof the JohnsHopkinsHospital.
Study Population
The study population consisted of all patients with
non-M3 AML, ages 18 to 60, presenting consecutively
to the SKCCC from November 1, 2004, to October
31, 2008. We followed the outcomes of these 133 pa-
tients through August 1, 2010. The cohorts consisted
of patients separated by FLT3/ITDmutational status,
cytogenetics, and treatments applied.
Diagnosis of FLT3/ITD Mutants
All patients had the status of their FLT3 internal
tandem duplication mutation determined by the Clin-
ical Laboratory Improvement Amendments (CLIA)-
certified test at the SKCCC. This assay identifies
internal FLT3 tandem duplication mutations via a sin-
gle multiplex DNA polymerase chain reaction. After
amplification, the polymerase chain reaction (PCR)
products are analyzed by capillary electrophoresis forlength mutations and resistance to EcoRV digestion
[11]. Each patient in the cohort had this test performed
at presentation, and the results were clinically available
to guide therapies.
Cytogenetics
Unfavorable-risk cytogenetics were defined ac-
cording to the Southwest Oncology Group/Eastern
Cooperative Oncology Group (SWOG/ECOG) clas-
sification [12] and included: del(5q)/-5, -7/del(7q), ab-
normality 3q, 9q, 11q, 20q, 21q, 17p, t(6;9), t(9;22),
and complex cytogenetics ($3 unrelated abnormali-
ties). Cytogenetics results were reviewed as provided
by the genetics laboratory. Abnormalities were further
classified as either complex cytogenetics ($3 unrelated
abnormalities) or normal (46 XX or 46 XY).
Treatment Schedule
All patients received their induction therapy at the
SKCCC. Fitness for intensive induction therapy was
determined using ECOG performance status at pre-
sentation, or by complicated medical comorbidities.
Two intensive induction regimens were employed:
(1) an institutional protocol of flavopiridol 50 mg/m2
given by 1-hour infusions daily  3 days beginning on
day 1, followed by 2 g/m2/72 hours cytarabine begin-
ning day 6, and 40 mg/m2 mitoxantrone on day 9
(FLAM) [13]; or (2) timed sequential therapy (TST)
[14] consistent with our institutional standard.This con-
sisted of cytarabine 667mg/m2 given by 24-hour contin-
uous infusion daily  3 and daunorubicin 45 mg/m2
intravenous push daily 3 both beginning on day 1, fol-
lowed by etoposide 200 mg/m2 intravenous infusion
over 3 hours daily on days 8 to 10 (AcDVP16) [15].
For patients receiving fully matched allogeneic
transplants from a sibling or unrelated donor, the pre-
parative regimen formyeloablativeHSCT consisted of
busulfan at 4 mg/kg/day orally or 3.2 mg/kg/day intra-
venously given in 4 daily divided doses for 4 consecu-
tive days, followed by cyclophosphamide (Cy) at 50
mg/kg intravenously for 2 consecutive days. The fifth
and subsequent doses of busulfan were adjusted ac-
cording to first-dose pharmacokinetic measurements
to achieve a target area under the curve of 800 to
1400 mol/L*min [16].
Graft-versus-host disease (GVHD)prophylaxiswas
the institutional standard of cyclophosphamide 50 mg/
kg/day given intravenously on days 3 and 4 after trans-
plantation [17,18]. Mesna (80% of cyclophosphamide
dose) was administered in 4 divided doses on all days
of cyclophosphamide administration. Tacrolimus was
given as additional GVHD prophylaxis in patients
posttransplantation.
Patients undergoing nonmyeloablative HSCT
from a haploidentical donor received a preparative
regimen on an institutional protocol. This
Table 1. Demographics of the FLT3/ITD and Wild-Type
Cohorts
Wild-Type FLT3/ITD
Total patients 102 31
Age (years) 49.5 51.7
Sex (% males) 51 52
WBC at diagnosis
( 1000/cu mm)
11.7 37.0
Type
De novo 62 26
Antecedent disorder 26 5
tAML 14 0
Cytogenetics
Favorable 11 1
Intermediate 42 23
Unfavorable 47 7
% Normal cytogenetics 35 74
% Transplanted 17 60
Transplant types
Matched sibling 6 4
Matched unrelated 9 5
Haploidentical 1 2
Syngeneic 1 0
Auto 1 0
WBC indicates white blood cells; AML, acute myelogenous leukemia.
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day from days 26 to 22, and total body irradiation
(TBI) 2 Gy on day 21. All patients received Cy 50
mg/kg on day 3, mycophenolate mofetil from day 4
to day 35, and tacrolimus from day 4 to day $50 [17].
All dosing of chemotherapeutic agents was based
on ideal body weight. Colony-stimulating factors
were not given. All supportive care measures were ad-
ministered according to institutional protocols and in-
cluded prophylaxis against Pneumocystis jirovecii,
Candida albicans, and herpes zoster/simplex infections.
All blood products except for the allografts were irra-
diated before transfusion. Cytomegalovirus (CMV)-
seronegative patients were given transfusions from
CMV-seronegative donors or leukoreduced blood
products if CMV products were unavailable. Support-
ive care measures were identical for all recipients of al-Figure 1. Patient disposition by FLT3/ITlografts and conventional chemotherapy. Nine of the
11 FLT3/ITD patients transplanted in CR1 required
an additional cycle of consolidative chemotherapy
prior to transplantation because of the time necessary
to prepare for the transplant.
Outcome Measures
The primary outcomemeasure wasOS.Other out-
comes analyzed were (1) event-free survival (EFS), de-
fined as the time to relapse or death, (2) relapse rate,
and (3) nonrelapse mortality (NRM), defined as time
to death censored at relapse. Kaplan-Meier curves
were used, and all treatment comparisons were by in-
tention to treat. These analyses were performed with
GraphPad Prism 4.RESULTS
The cohort included 102 patients with wild-type
(WT) FLT3 and 31 with FLT3/ITD mutations. The
demographics of each cohort are shown in Table 1.
The median age at diagnosis was 49.5 years for the pa-
tients with WT FLT3 and 51.7 years for the patients
with FLT3/ITD. The median white blood cell
(WBC) count at diagnosis was 37,000/mL for the
FLT3/ITD patients and 11,700/mL for the WT pa-
tients.Most (24/31)of theFLT3/ITDpatients hadnor-
mal cytogenetics; 2 of these patients had unfavorable
cytogenetics, and 1 had favorable. Of the WT cohort,
47 had unfavorable cytogenetics, 44 had intermediate
(36 normal), and 11 had favorable. The WT cohort
also included 14 patients with treatment-related AML
and 26 with antecedent hematologic disorders.
Figure 1 outlines the disposition of patients by
therapy. There were a total of 6 induction deaths
between the 2 groups. Fourteen patients were deemed
unfit for intensive induction therapy by ECOG [12]
performance status at presentation or complicated
medical comorbidities. Two were in the inductionD mutation status and treatment.
Figure 3. Event-free survival of FLT3/ITD patients transplanted in CR1.
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mutations. These patients were excluded from further
analyses. All other patients received 1 of 2 intensive
regimens as previously described.
The median OS from diagnosis for all 119 patients
receiving intensive inductionwas19.6months.Theme-
dian survival times for favorable, intermediate, and un-
favorable cytogenetic groups were 57.3, 18.9, and 9.4
months, respectively. The median OS for the FLT3/
ITD AML patients was 19.3 (range: 0.0-69.9) months
and was similar to the median OS of the WT patients
of 15.5 (range: 0.7-64.6) months (P 5 .56) (Figure 2).
Induction success was similar between the 2 groups,
with remissions obtained in 65% (20/31) of the
FLT3/ITD patients and 61% (52/85) of WT patients.
Of the 20 FLT3/ITD patients in CR1, 11 (55%)
underwent allogeneic HSCT in CR1 (4 myeloablative,
HLA-matched sibling donors, 5 myeloablative, HLA-
matched unrelated donors, and 2 nonmyeloablative
haploidentical related donors). The remaining 9
FLT3/ITD patients in CR1 did not go to allogeneic
HSCT because of lack of a suitable donor or preclud-
ing comorbidities following induction. The median
relapse-free survival (RFS) in the FLT3/ITD non-
transplant group was 8.6 months (range: 5.3-43.3
months), which was significantly shorter than the
54.1 months (range: 6.4-69.9 months) in the FLT3/
ITD transplant (P 5 .03) (Figure 3).
In contrast, of the 52WTpatient inCR1, 17 (33%)
of WT patients underwent HSCT in CR1 (5 myeloa-
blative HLA-matched sibling donors, 9 myeloablative,
HLA-matched unrelated donors, 1 syngeneic trans-
plant, 1 autologous transplant, and 1 nonmyeloablative
haploidentical related donor) (Table 1). The median
OS in the WT, non-HSCT group was 57.3 (range:Figure 2. Overall survival of 133 patients by FLT3/ITDmutation status.3.9-64.4) months, whereas the median OS in the WT
transplant group is .60 months (P 5 .02). Figure 4
demonstrates the difference in the survival curves for
all the patients in both cohorts based on any transplant
during their course.DISCUSSION
As FLT3/ITD mutations fall into the category of
unfavorable risk, it has been hypothesized that these
patients will benefit from allogeneic HSCT in CR1
to improve the outcomes and survival. The date to
prove or refute this hypothesis remains controversial.
In 2005, Gale and colleagues [19] at the Medical
Research Council of the United Kingdom investigated
whether AML patients with a FLT3/ITD mutation
have an improved outcome if they undergo HSCT,
compared to similar patients receiving chemotherapy.
In a retrospective analysis of patients, comparisons
weremade between patients receiving autografts versus
allografts, and between patients receiving autograftsFigure 4. Overall survival of FLT3/ITD and WT patients transplanted
versus no transplant.
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mutation was an accurate independent predictor of re-
lapse, and it remained prognostic for increased relapse
even in those patients who received a transplant. The
authors therefore concluded that there was insufficient
evidence that FLT3/ITD status should influence the
decision to transplantation [19]. However, the data
analysis in the 2005 study limited the application of
the results, because there was no direct comparison be-
tween FLT3/ITD patients receiving allografts and
those receiving chemotherapy alone [20].
The impact of different consolidation therapies on
OS, and on the probability of relapse in patients with
FLT3/ITD mutation versus WT was studied by the
German study initiative leukemia group [21]. The
study showed that after a median follow-up of 53
months, OS was not significantly different between
FLT3/ITD patients and WT. In contrast, chemo-
therapy alone as consolidation therapy had inferior
OS, and increased rates of relapse in the patients
with FLT3/ITD mutation [21].
Given the conflicting results in these larger co-
horts, we sought to evaluate our experience of 31
FLT3/ITD patients with a comparable OS outcome
to that for the 102 patients with WT FLT3 over the
same 4-year time period. Although the transplanted
population of FLT3/ITD patients is quite small (11
patients), this finding is of clinical interest and adds
to the previous studies suggesting an advantage for
transplantation in this group. Our analysis is derived
from a consecutive series of newly diagnosed AML pa-
tients and lacks the potential selection biases inherent
in data derived from prospective trials. As such, our
report represents a ‘‘real-world’’ perspective on the
challengingmanagement of FLT3/ITDAML.Histor-
ically, the OS for AML patients with the FLT3/ITD
mutation is significantly worse than for AML patients
lacking this mutation. The outcomes presented here
are comparable to other published results [18,22] and
suggest that our patient set and the responses to
treatment are representative of a typical adult AML
population, including the influence of unfavorable
cytogenetics in nearly half the WT cohort. Although
2 different induction therapies were used, these
subgroups were fairly well balanced as evidenced by
the percentage of patient achieving a CR1 in each
treatment group. Inclusion of the larger WT cohort
is intended to contrast with the FLT3/ITD group
and develop the background for the generalizability
of the groups. It is possible that our institution’s
use of posttransplant cyclophosphamide to mitigate
GVHD contributed to the apparent benefit of
allogeneic transplant for FLT3/ITD patients.
Certainly, this approach did allow us to consider all
available donor transplants for both cohorts,
especially the FLT3 cohort, including haploidentical
and unrelated. However, the rates of relapsein hematologic malignancies after posttransplant
cyclophosphamide are comparable to the rates of
relapse after more traditional immunosuppression in
other centers [17]. Furthermore, other groups have
suggested that allogeneic transplantation is the pre-
ferred consolidation therapy for FLT3/ITD AML
[21]. This would suggest that this approach could be
considered at other institutions willing to proceed to
alternative donor transplants. During this time period,
our institution was not routinely testing NPM1 muta-
tion status in all patients. The impact this additional
information would have had on the outcomes of these
patients is not known. We have also not generalized
this approach to FLT3 TKD mutations given their
controversial prognostic significance [23-25].
The surprising outcome for the FLT3/ITD group
may be partly attributed to our aggressive pursuit of al-
logeneic BMT in CR1 within this group (60% of
FLT3/ITD versus 17% withWT). Our single institu-
tion study of consecutively treated AML patients sup-
ports the hypothesis that allogeneic transplant in early
CR1 may improve the long-term outcomes for pa-
tients with FLT3/ITD AML.ACKNOWLEDGMENTS
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